YOU SEARCHED BY...
SEARCH BY...
Contract Service Directory
Country
- Argentina(2)
- Australia(5)
- Austria(3)
- Belgium(3)
- Brazil(1)
- Canada(91)
- China(20)
- Colombia(1)
- Denmark(3)
- Egypt(1)
- Finland(2)
- France(22)
- Georgia(1)
- Germany(47)
- Greece(1)
- Hong Kong(2)
- Hungary(2)
- India(97)
- Israel(5)
- Italia (6)
- Japan(2)
- Kazakhstan(1)
- Malta(1)
- Mexico(1)
- Norway(1)
- Peru(1)
- Poland(1)
- Portugal(4)
- Russia(1)
- Singapore(1)
- Slovenia(1)
- South Korea(2)
- Spain(10)
- Sri Lanka(1)
- Sweden(2)
- Switzerland(28)
- Taiwan(5)
- The Czech Republic(1)
- The Netherlands(4)
- Turkey(2)
- Ukraine(1)
- United Kingdom(84)
- United States(999)
Contract Service Directory
Company Headquarters
400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
Company Description
Emergent provides contract development and manufacturing services for bulk drug substances and parenteral drug products. Our Fill/Finish services include vials and syringes for both liquid and lyophilized products. We also offer lyo cycle development and optimization. Our global manufacturing network currently produces over 20 commercial products and support a host of clinical stage programs.
Contract Service Directory
- Accelerated Stability Studies
- Analytical Laboratory Services
- Analytical Validation Studies
- Assay Development
- Biosimilars
- Cell Line Construction & Development
- Clinical Trials, Phase I
- Clinical Trials, Phase II
- CMC (Chemistry, Manfacturing & Controls)
- Contract Development and Manufacturing Organization (CDMO)
- Contract Manufacturing
- Distribution, Commercial
- Downstream Processing
- Fermentation
- Filling, Syringe
- Filling, Vial
- Lot Release Testing
- Lyophilization
- Manufacturing, Aseptic Fill/Finish
- Manufacturing, Clinical Trials Supply
- Manufacturing, Dose Form, Sterile
- Manufacturing, Injectables
- Manufacturing, Liquids
- Manufacturing, Lyophilized Products
- Manufacturing, Microbial-based Therapeutic Proteins
- Manufacturing, Oligonucleotides
- Manufacturing, Parenterals, Small Volume
- Manufacturing, Peptides
- Manufacturing, Proteins
- Manufacturing, Syringes, Pre-filled
- Manufacturing, Vaccines
- Manufacturing, Veterinary
- Packaging, Injectables
- Parenterals, Syringe Filling
- Parenterals, Vial Filling
- Process Development/Scale-Up Services
- Process Validation Studies
- Purification
- QA/QC
- Stability Studies
- Stability, ICH
- Sterile Filling
- Sterility Testing
- Syringe Filling
- Technology Transfer
Contract Services Directory
Content From Emergent BioSolutions, Inc.
-
Emergent Contract Manufacturing & Services
Download our CMO Services BrochureLiterature / Brochures Released on 03.06.2019
-
Emergent’s Lyophilization Capabilities
INTEGRATED LYO CYCLE DEVELOPMENT AND MANUFACTURING SERVICESLiterature / Brochures Released on 03.06.2019
-
Emergent BioSolution - Corporate Fact Sheet
At Emergent BioSolutions our mission is to protect and enhance life.Literature / Brochures Released on 03.06.2019
-
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study
GAITHERSBURG, Md., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B, the company…News Releases Released on 02.01.2017
-
Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55
GAITHERSBURG, Md., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, has approv…News Releases Released on 01.27.2017
-
Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlo
GAITHERSBURG, Md., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2016 financial results and guidance for 2017. Daniel J. Abdun-Nabi, president and chief execut…News Releases Released on 01.09.2017
-
Emergent BioSolutions to Participate in First Quarter 2017 Investor Conferences
GAITHERSBURG, Md., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences durin…News Releases Released on 12.29.2016
-
Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin
GAITHERSBURG, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its botulism antitoxin, BAT&…News Releases Released on 12.12.2016
-
Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy
Company signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021 BARDA issues noti…News Releases Released on 12.08.2016
-
Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of Directors
GAITHERSBURG, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Kathryn C. Zoon, Ph.D. to the company’s Board of Directors. Dr. Zoon is currently a Scientist E…News Releases Released on 11.08.2016
-
Emergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial Results
GAITHERSBURG, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2016. FINANCIAL HIGHLIGHTS The following fin…News Releases Released on 11.07.2016
-
Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 6, 2015 at 8:00 am (Eastern Time).News Releases Released on 07.23.2015
-
Emergent Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies
Company Receives Its First Ebola-Related BARDA Task OrderNews Releases Released on 07.20.2015
-
Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences
Emergent Leverages Manufacturing and Plasma Fractionation Expertise to Create Opportunities for Future Revenue GrowthNews Releases Released on 05.19.2015
-
Oxford U., GSK, and Emergent Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates
OXFORD, U.K., LONDON and GAITHERSBURG, Md., May 13, 2015 (GLOBE NEWSWIRE) -- A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) as a pri…News Releases Released on 05.13.2015
